SYS-6010

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameSYS-6010
Drug Alias NameSYS6010SYS-6010CPO-301CPO301
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesJushi Biopharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesConjupro Biotherapeutics IncShanghai Jmt-Bio IncCSPC Megalith Biopharmaceutical Co Ltd +[5] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[7] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A